1. Home
  2. ZURA vs DPRO Comparison

ZURA vs DPRO Comparison

Compare ZURA & DPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZURA
  • DPRO
  • Stock Information
  • Founded
  • ZURA 2022
  • DPRO 1998
  • Country
  • ZURA United States
  • DPRO Canada
  • Employees
  • ZURA N/A
  • DPRO N/A
  • Industry
  • ZURA Biotechnology: Biological Products (No Diagnostic Substances)
  • DPRO Aerospace
  • Sector
  • ZURA Health Care
  • DPRO Industrials
  • Exchange
  • ZURA Nasdaq
  • DPRO Nasdaq
  • Market Cap
  • ZURA 69.9M
  • DPRO 81.2M
  • IPO Year
  • ZURA N/A
  • DPRO N/A
  • Fundamental
  • Price
  • ZURA $2.04
  • DPRO $4.87
  • Analyst Decision
  • ZURA Buy
  • DPRO Strong Buy
  • Analyst Count
  • ZURA 10
  • DPRO 2
  • Target Price
  • ZURA $12.67
  • DPRO $6.50
  • AVG Volume (30 Days)
  • ZURA 367.0K
  • DPRO 1.7M
  • Earning Date
  • ZURA 08-14-2025
  • DPRO 08-11-2025
  • Dividend Yield
  • ZURA N/A
  • DPRO N/A
  • EPS Growth
  • ZURA N/A
  • DPRO N/A
  • EPS
  • ZURA N/A
  • DPRO N/A
  • Revenue
  • ZURA N/A
  • DPRO $5,250,872.00
  • Revenue This Year
  • ZURA N/A
  • DPRO $69.58
  • Revenue Next Year
  • ZURA N/A
  • DPRO $100.68
  • P/E Ratio
  • ZURA N/A
  • DPRO N/A
  • Revenue Growth
  • ZURA N/A
  • DPRO 17.08
  • 52 Week Low
  • ZURA $0.97
  • DPRO $1.55
  • 52 Week High
  • ZURA $5.07
  • DPRO $7.31
  • Technical
  • Relative Strength Index (RSI)
  • ZURA 65.78
  • DPRO 54.08
  • Support Level
  • ZURA $1.44
  • DPRO $3.85
  • Resistance Level
  • ZURA $2.09
  • DPRO $4.55
  • Average True Range (ATR)
  • ZURA 0.14
  • DPRO 0.35
  • MACD
  • ZURA 0.03
  • DPRO 0.02
  • Stochastic Oscillator
  • ZURA 78.31
  • DPRO 71.33

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.

About DPRO Draganfly Inc.

Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The three segments are Drones, Vital (Vital Intelligence), and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Vital segment derives its revenue from the sale of products that measure vitals to help detect symptoms from large groups of people from a distance. The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.

Share on Social Networks: